By Lee Carroll, BHSc (WHM), BSc
A Clue at the Membrane
I track the ergothioneine literature pretty closely.
Honestly, it’s turned into a bit of an obsession.
Not because I’m looking for another shiny antioxidant story…
Rather, because ergothioneine (ERGO) is unique and almost meets the definition of a vitamin. Why would evolution make ERGO transporters if they weren’t needed? Our biology is set up for it. In all my years, I haven’t seen a more coherent story around a molecule that looks new to modern science but has been part of our biology all along. Technically, it’s not even new, being discovered in 1909, but the identification of the ERGO transporter in 2015 changed everything.
I’ve had lots of hunches throughout my career. For example, I was one of the first to lecture on and link the vascular endothelial glycocalyx to herbal or nutraceutical interventions. At the time, the endothelial glycocalyx was largely confined to critical care and vascular biology literature, with almost no discussion of botanical or integrative therapeutic strategies.
In real-world clinical decision-making, you end up leaning on hunches. You hold tradition in one hand, data in the other, and when you’re stuck between A and B, it’s often intuition that tips the scale. So, I have learned to trust my intuition.
Right now, my hunch is this:
Ergothioneine may be entering a new phase of understanding, and a 2025 paper by Villalaín and colleagues may prove to be the first clear indication (1).
This blog explores the potential ramifications of this emerging shift in ERGO biology.
ERGO’s Hydrophilic Nature Under Scrutiny
We have long treated ERGO as an exclusively water-phase antioxidant because it is highly hydrophilic. By this logic, it can only move in aqueous zones and should not interact with membranes. Indeed, it is well-known that ergothionine requires its transporter (OCTN1) to cross membranes and enter cells.
A 2025 publication in Membranes suddenly challenges our assumptions regarding ERGO’s nature here (1).
José Villalaín sought to clarify whether ERGO can interact with membranes. He employed a membrane model using molecular dynamics simulations to investigate this. As ERGO is known to be hydrophilic, he did not examine the membrane’s deep lipid bilayer. He was specifically interested in the zone where membrane contacts the aqueous compartment: the membrane interphase.
The results of Villalaín’s investigation surely sent a minor shockwave through the ERGO academic community! It’s an unexpected revelation, and the implications for clinical application are something I would like to explore.
Surprise at the Membrane Interphase
Tautomers are chemical forms in which different structural isomers readily interconvert. Because ERGO is a tautomer, it has two interconverting forms, both of which were modelled by Villalaín. He found they reacted differently to the membrane interphase:
- Thione (major, more stable form, found at normal cellular pH): spontaneously inserts itself into the membrane interphase, remains monomeric.
- Thiol (antioxidant-active form, occurs in stressed cells with lower pH): rapidly partitions itself in the aqueous phase, i.e., no behavior at the membrane interphase.
The thione doesn’t remain anchored to the membrane interphase after it slots in, but can detach again into the aqueous zone, and so it appears to readily exchange these positions. Does this mean the interphase localization could serve as a storage site for the thione until the cell needs support? This is what I’m thinking.
None of this indicates ERGO is amphiphilic in the classic sense; it remains hydrophilic overall but appears capable of transiently occupying the membrane interphase without disrupting membrane structure.
Let’s quickly cover the nerdy specifics of how ERGO sits in this region:
- ERGO’s sulfur atom tends to nestle slightly above the cholesterol oxygen atoms
- ERGO’s trimethylammonium nitrogen and oxygen atoms sit slightly above the phosphate level
- ERGO does not extend beyond the position of cholesterol oxygens and does not modify hydrocarbon chain fluidity
ERGO doesn’t behave like a cholesterol-binding ligand; it occupies the interphase region and forms transient interactions with surrounding lipids. It only hovers in this space, bound by phosphate headgroups and cholesterol oxygen. Villalaín also examined ERGO’s local lipid neighborhood and found cholesterol is not enriched around it (relative to bulk), suggesting ERGO occupies the phosphate–cholesterol boundary region without preferentially associating with cholesterol-rich microdomains.
This creates a neat paradox: the thiol form is often treated as the ‘more reactive antioxidant,’ yet it’s the thione that parks at the membrane interphase. My working model is that thione ERGO acts as a low-reactivity sentinel, positioned where lipid peroxidation begins, while local stress could shift redox behavior or tautomer balance at the interface. That would make ERGO less of a bulk ROS mop and more of a boundary buffer.
Villalaín’s results are, of course, based only on simulations, so further lab work will be required to confirm their validity. It looks like a very reasonable scenario, however, and I’m willing to bet that it is indeed the case. This changes the way I am thinking about ERGO clinically, and I’ll share those ideas in a moment.
Why ERGO Matters at Boundaries
In real biology, oxidative stress is not evenly distributed at the cellular level. A disproportionate amount of oxidative injury begins at biological boundaries (think membrane surfaces, lipoproteins, endothelial barrier interfaces, organelle membranes) rather than in bulk aqueous compartments.
The membrane interphase is a boundary layer where aqueous oxidants meet lipid architecture. Here, membrane proteins sense and signal, and small oxidative disturbances can lead to dysfunction. If you wanted to position a molecular “sentinel” to carefully manage early oxidative stress, this is exactly where it would need to be. My sense is that the next wave of ERGO discussion will focus on its work at the membrane boundary.
If thione ERGO reversibly occupies the membrane interphase as this in silico work implies, we have to ask: what kinds of oxidative insults happen there that fit with ERGO’s known protective mechanisms? Basically, what is ERGO most likely to be doing there?
Let’s consider it logically.
Hunch #1: ERGO may directly buffer destructive oxysterols
When we consider membrane and barrier injury, cholesterol itself isn’t the problem. The problem begins when cholesterol becomes oxidized.
7-Ketocholesterol (7KC) forms when cholesterol at the membrane interphase suffers oxidative damage to the sterol ring (the C7 position). This generates a radical cascade that chemically modifies the sterol structure in the bilayer.
Unlike native cholesterol, 7KC is not structurally neutral. It disturbs membrane packing, alters lipid–protein interactions, and amplifies inflammatory signaling. It is strongly associated with atheromatous plaque development and cardiometabolic risk states such as hypercholesterolemia and diabetes mellitus (2). The interphase region is already a chemically active boundary layer, and the introduction of an oxysterol like 7KC further increases redox instability in that zone.
In endothelial models, 7KC drives damaging processes that result in loss of membrane viability, inflammatory gene programs and COX‑2 activity, and tight‑junction disruption. In that same context, intracellular ERGO mitigates these effects, suggesting it’s positioned to interrupt downstream 7KC consequences (3). Importantly, this protection depends on OCTN1-mediated uptake, implying that ERGO’s intracellular localization is biologically directed rather than the result of passive extracellular scavenging.
Take-away: if thione ERGO sits in the membrane interphase, it is in the perfect position to buffer the damage that initiates with 7KC before it cascades into more oxidative reactions, where it performs a specialized cytoprotective role.
#2: The endothelium is the battleground
Cardiovascular disease doesn’t just start “in the blood”; it starts at interfaces. These zones are where lipoproteins meet the endothelium, oxidized lipids hit membranes, and tight junctions (and the glycocalyx) take the first hit. If Hunch #1 is about one nasty molecule (7KC), Hunch #2 is the wider point: cardiovascular risk is boundary biology.
Observational data link higher plasma ERGO with reduced cardiovascular disease risk and mortality, as well as reduced overall mortality (4). ERGO is actively taken up by endothelial cells (5), and in classic vessel preparations, it supports endothelium‑dependent relaxation, consistent with a role in preserving endothelial function under oxidative load. It’s also been linked to reduced monocyte–endothelial adhesion, one of the earliest and most boundary-specific steps in atherogenesis (6).
Villalaín’s report elegantly demonstrates how ERGO might be behaving as a specialist protective agent against cardiovascular disease.
Take‑away: if ERGO reinforces endothelial integrity at sites of first oxidative contact, vascular health may reflect how well that interface is loaded relative to lifetime redox exposure, not merely whether plasma levels avoid deficiency.
#3: The BBB is the hidden stage for cognitive ageing
The blood-brain barrier (BBB) is another boundary to consider, and ERGO seems strongly aligned with protecting brain health and function.
ERGO levels decline with age and are lower in mild cognitive impairment (7). In memory-clinic and dementia cohorts, lower ERGO tracks with cerebrovascular disease/neurodegeneration markers and predicts faster cognitive and functional decline over time (8,9). Low ERGO also predicts faster progression to Alzheimer’s disease (10).
Human interventional studies point in the same direction. More than protection, there is evidence of cognitive improvement (11-13) and benefits for sleep outcomes, another domain that often deteriorates alongside neurovascular ageing (14,15).
So now we consider ERGO at the interphase again. Models of human brain microvascular endothelial environments relevant to the BBB indicate oxysterol-based stress (e.g., 7KC) eventually disrupts tight-junction architecture and pushes cells toward inflammatory and mitochondrial stress, and ERGO is protective here (3,4).
Take-away: if a portion of ERGO resides at neurovascular membrane boundaries, its contribution to cognitive resilience depends less on acute dosing and more on sustained tissue saturation at the BBB, where it may protect integrity and reduce influx of damaging molecules.
#4: Red Blood Cell Insurance
Red blood cells (RBCs) live under relentless oxidative pressure. Hemoglobin auto-oxidation continuously generates reactive oxygen species, and without a nucleus, RBCs have limited capacity for repair. When oxidative injury stiffens the membrane, it loses vital flexibility, compromising capillary transit and oxygen delivery.
The current view is that RBC enrichment likely reflects a need for specialist antioxidant defense under relentless oxidative pressure (16).
RBCs have one of the highest capacities to store ERGO, though they don’t accumulate it as mature cells, but are preloaded with it during erythropoiesis. This means that dietary deficiencies translate into suboptimal RBC levels, and the months-long RBC lifespan dictates the lag period before any intake can help.
Take-away: if thione ERGO can stabilize membrane interfaces, it likely plays a key role in preserving RBC functionality and lifespan; however, months of high dosing could be required before physiological changes can be made after a state of ERGO deficiency.
What does this tell us about how to dose?
It sounds like a common assumption in antioxidant talk that dose equals scavenging capacity. If the Villalaín simulations are true, however, they suggest a second frame: dose equals occupancy or coverage. If meaningful function relies on presence at membrane interphases across a large tissue surface area, then dosing becomes, in part, a question of physical distribution rather than simple biochemical scavenging.
My dosing framework has always been three-tiered; what is evolving is how I calibrate the upper ranges in light of emerging membrane biology. What follows is not a formal guideline, but my current working refinement, informed by mechanistic insight, clinical observation, and the substantial safety margin reported for ERGO. I offer it as a model for thoughtful clinical experimentation.
- Baseline physiological support: 5–10 mg/day
- Active resilience / moderate oxidative demand: 10–40 mg/day
- Tissue loading / high-demand states (exploratory range): 40–100 mg/day
The upper range reflects a tissue-loading hypothesis rather than an acute antioxidant strategy and should be approached as exploratory within established safety margins.
We do not yet fully understand the pharmacokinetics of ERGO distribution across tissues. OCTN1-mediated uptake appears saturable, and different cell types likely compete for available circulating ERGO based on transporter density and metabolic demand. It is plausible that high-turnover or high-expression compartments load first, with more distal or lower-expression tissues accumulating ERGO more gradually over time. If membrane interphases serve as reversible residency sites, then sustained intake may progressively expand distributed tissue buffering capacity rather than produce immediate systemic effects. Such a loading-dependent model would align with the time-dependent effects observed in longer-duration human studies, where measurable shifts in cognition, sleep, or cellular markers emerge over weeks and months rather than days.
ERGO has demonstrated a wide safety margin, with a no-observed-adverse-effect level (NOAEL) that, when converted to a human-equivalent dose, is roughly 9,000 mg per day (17). The ranges discussed here remain well below that threshold, supporting cautious exploration within clinical practice.
Reframing ERGO Biology
ERGO is not just another circulating antioxidant. It operates in the cytoplasm, where it supports redox balance, interfaces with sulfur metabolism pathways such as MPST (18) and CSE, and provides backup protection when glutathione is depleted. That foundation remains solid. Its influence on redox-sensitive signaling networks such as NF-κB and Nrf2 remains central; the membrane insight simply adds a structural dimension to that biology.
What the membrane interphase model potentially adds is a second dimension. Traditionally, ergothioneine has not been considered to have a defined storage organ or centralized reservoir; it is viewed as being transported into cells and retained according to transporter activity and tissue demand. If membrane interphases function as reversible retention sites, ergothioneine may instead rely on a distributed, tissue-wide retention architecture embedded across cellular boundaries.
A portion of ERGO may reside at the membrane boundary, positioned at a structural zone where oxidative injury often begins. If that proves correct, ERGO is not simply diffusing through aqueous compartments. It is spatially organized at sites of vulnerability, contributing to local buffering capacity where lipid peroxidation, oxysterol formation, and inflammatory signaling are initiated.
Most discussions around ERGO intake are framed around deficiency prevention or epidemiological association. Plasma levels are correlated with disease risk, and shortfalls are estimated in milligram ranges. But that framework may be anchored to avoiding pathology, not optimizing resilience.
Modern humans live under sustained metabolic and environmental pressures that are historically unusual. Chronic hyperglycemia, persistent postprandial oxidative stress, air pollutants, inflammatory dietary patterns, circadian disruption, and psychological stress all create ongoing redox demand. These are not acute survival stressors. They are cumulative, membrane-active burdens.
If ERGO contributes not only to cytosolic redox balance but also to interphase buffering capacity, then optimal tissue loading may be a function of total stress exposure rather than minimal disease prevention thresholds. Adequate intake may not be the same as optimal buffering.
We do not yet know what an optimal intracellular ERGO concentration looks like. But if membranes serve as dynamic distribution depots, and if ERGO participates in maintaining structural resilience under chronic oxidative strain, then the question is no longer whether ERGO works. It becomes a question of whether we are loading the system sufficiently for the world we now inhabit.
References
- Villalaín J. (2025). Ergothioneine thione spontaneously binds to and detaches from the membrane interphase. Membranes, 15(11), 328. https://doi.org/10.3390/membranes15110328
- Leow, D. M., Cheah, I. K., Fong, Z. W., Halliwell, B., & Ong, W. Y. (2023). Protective Effect of Ergothioneine against 7-Ketocholesterol-Induced Mitochondrial Damage in hCMEC/D3 Human Brain Endothelial Cells. International Journal of Molecular Sciences, 24(6), 5498. https://doi.org/10.3390/ijms24065498
- Koh, S. S., Ooi, S. C., Lui, N. M., Qiong, C., Ho, L. T., Cheah, I. K., Halliwell, B., Herr, D. R., & Ong, W. Y. (2021). Effect of Ergothioneine on 7-Ketocholesterol-Induced Endothelial Injury. Neuromolecular Medicine, 23(1), 184–198. https://doi.org/10.1007/s12017-020-08620-4
- Smith, E., Ottosson, F., Hellstrand, S., Ericson, U., Orho-Melander, M., Fernandez, C., & Melander, O. (2020). Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart, 106(9), 691–697. https://doi.org/10.1136/heartjnl-2019-315485
- Li, R. W., Yang, C., Sit, A. S., Kwan, Y. W., Lee, S. M., Hoi, M. P., Chan, S. W., Hausman, M., Vanhoutte, P. M., & Leung, G. P. (2014). Uptake and protective effects of ergothioneine in human endothelial cells. The Journal of Pharmacology and Experimental Therapeutics, 350(3), 691–700. https://doi.org/10.1124/jpet.114.214049
- Paul B. D. (2022). Ergothioneine: a stress vitamin with antiaging, vascular, and neuroprotective roles?. Antioxidants & Redox Signaling, 36(16-18), 1306–1317. https://doi.org/10.1089/ars.2021.0043
- Cheah, I. K., Feng, L., Tang, R. M. Y., Lim, K. H. C., & Halliwell, B. (2016). Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? Biochemical and Biophysical Research Communications, 478(1), 162–167. https://doi.org/10.1016/j.bbrc.2016.07.074
- Wu, L. Y., Cheah, I. K., Chong, J. R., Chai, Y. L., Tan, J. Y., Hilal, S., Vrooman, H., Chen, C. P., Halliwell, B., & Lai, M. K. P. (2021). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radical Biology and Medicine, 177, 201–211. https://doi.org/10.1016/j.freeradbiomed.2021.10.019
- Wu, L. Y., Kan, C. N., Cheah, I. K., Chong, J. R., Xu, X., Vrooman, H., Hilal, S., Venketasubramanian, N., Chen, C. P., Halliwell, B., & Lai, M. K. P. (2022). Low plasma ergothioneine predicts cognitive and functional decline in an elderly cohort attending memory clinics. Antioxidants, 11(9), 1717. https://doi.org/10.3390/antiox11091717
- Oka, T., Matsuzawa, Y., Tsuneyoshi, M., Nakamura, Y., Aoshima, K., Tsugawa, H., & Alzheimer’s Disease Metabolomics Consortium (2024). Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohort. Scientific Reports, 14(1), 6797. https://doi.org/10.1038/s41598-024-56837-1
- Watanabe, N., Hakui, Y., Mukai, K., Takahashi, M., Ohashi, K., & Ogawa, S. (2020). Effect of ergothioneine on the cognitive function improvement in healthy volunteers and mild cognitive impairment subjects: A randomized, double-blind, parallel-group comparison study. Japanese Pharmacology & Therapeutics, 48(4), 685–697.
- Zajac, I. T., Kakoschke, N., Kuhn-Sherlock, B., & May-Zhang, L. S. (2025). The effect of ergothioneine supplementation on cognitive function, memory, and sleep in older adults with subjective memory complaints: a randomized placebo-controlled trial. Nutraceuticals, 5(3), 15. https://doi.org/10.3390/nutraceuticals5030015
- Yau, Y. F., Cheah, I. K., Mahendran, R., Tang, R. M., Chua, R. Y., Goh, R. E., Feng, L., Li, J., Kua, E. H., Chen, C., & Halliwell, B. (2024). Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. Journal of Alzheimer’s Disease, 102(3), 841–854. https://doi.org/10.1177/13872877241291253
- Katsube, M., Watanabe, H., Suzuki, K., Ishimoto, T., Tatebayashi, Y., Kato, Y., & Murayama, N. (2022). Food-derived antioxidant ergothioneine improves sleep difficulties in humans. Journal of Functional Foods, 95, 105165. https://doi.org/10.1016/j.jff.2022.105165
- Okumura, H., Araragi, Y., Nishioka, K., Yamashita, R., Suzuki, T., Watanabe, H., Kato, Y., & Murayama, N. (2025). Estimation and validation of an effective ergothioneine dose for improved sleep quality using physiologically based pharmacokinetic model. Food Science & Nutrition, 13(6), e70382. https://doi.org/10.1002/fsn3.70382
- Thomas, T. A., Francis, R. O., Zimring, J. C., Kao, J. P., Nemkov, T., & Spitalnik, S. L. (2024). The Role of Ergothioneine in Red Blood Cell Biology: A Review and Perspective. Antioxidants, 13(6), 717. https://doi.org/10.3390/antiox13060717
- Turck, D., Bresson, J.-L., Burlingame, B., Dean, T., Fairweather-Tait, S., Heinonen, M., Hirsch-Ernst, K.-I., Mangelsdorf, I., McArdle, H., Naska, A., Neuhäuser-Berthold, M., Nowicka, G., Pentieva, K., Sanz, Y., Siani, A., Sjödin, A., Stern, M., Tomé, D., Vinceti, M., & Willatts, P. (2016). Safety of synthetic L-ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal, 14(11), 4629. https://doi.org/10.2903/j.efsa.2016.4629
- Sprenger, H. G., Mittenbühler, M. J., Sun, Y., Van Vranken, J. G., Schindler, S., Jayaraj, A., Khetarpal, S. A., Vargas-Castillo, A., Puszynska, A. M., Spinelli, J. B., Armani, A., Kunchok, T., Ryback, B., Seo, H. S., Song, K., Sebastian, L., O’Young, C., Braithwaite, C., Dhe-Paganon, S., Burger, N., Mills, E. L., Gygi, S. P., Paulo, J. A., Arthanari, H., Chouchani, E. T., Sabatini, D. M., & Spiegelman, B. M. (2025). Ergothioneine controls mitochondrial function and exercise performance via direct activation of MPST. Cell Metabolism, 37(4), 857–869.e9. https://doi.org/10.1016/j.cmet.2025.01.024